Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...
Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Bristol Myers Squibb Canada (BMS) is pleased to announce that OPDIVO® SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements. Quebec is the first ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
SAN DIEGO — For almost 50 years, oral levodopa (LD) has reigned supreme as the major treatment for Parkinson's disease (PD). Although it is still overall the most effective oral therapy, better routes ...
Allen CH, Etzwiler LS, Miller MK, et al for the Increased Flow Utilizing Subcutaneously-Enabled-(INFUSE) Pediatric Rehydration Study Collaborative Research Group Oral rehydration is the preferred ...
BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion ...
Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
MAHWAH, N.J., October 31, 2024--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results